Mr. Carl Sterritt, MSc., MBA co-founded Shield Holdings AG in 2008 and serves as its Chief Executive Officer. Mr. Sterritt serves as the Chief Executive Officer of Phosphate Therapeutics Ltd. Mr. Sterritt serves as Senior Vice President of Commercial Development at Lung LLC. He has over 15 years experience in pharmaceutical development and commercialisation. In the late 90s, whilst working at Quintiles, he became involved in orphan diseases through his involvement in the development of United Therapeutics' Remodulin®, a treatment for pulmonary hypertension. He joined United Therapeutics to establish its European operations in preparation for the marketing approval of Remodulin®. He ran the subsidiary successfully for 6 years and in collaboration with physicians from the University of Giessen in Germany, was responsible for United Therapeutics' decision to develop and commercialise a new inhaled formulation of Remodulin® which has been launched in the US as Tyvaso™. In 2006, Mr. Sterritt joined Encysive Pharmaceuticals to lead its European commercial operations. In this role, he was instrumental in the rapid growth of Encysive's European operations and the successful commercial launch of Thelin™ for the treatment of pulmonary arterial hypertension. He serves as a Director of Shield Holdings AG. Mr. Sterritt has an academic background in life sciences and an MBA from Henley Management College.

 Life sciences and MBA